Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Elevated baseline C-reactive protein levels correlate with a reduced clinical response to adalimumab, despite the drug's overall efficacy. Patients with higher inflammation levels may experience ...